You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Background
The use of digital biomarkers to assess cognition in Alzheimer’s disease (AD) offers scalable, efficient alternatives to paper‐and‐pencil tests. Validating these tools against clinical and biomarker‐defined groups is critical for their adoption in research, clinical trials and clinical contexts. This study evaluates the performance of a remote, unsupervised cognitive assessment (FLAME‐Factors of Longitudinal Attention, Memory and Executive Function) in distinguishing cognitive profiles across diagnostic categories and amyloid status in two cohorts from BBRC.
Method
Cognitively normal (CN) participants from ALFA+ cohort and subjective cognitive decline (SCD) or mild cognitive impairment (MCI) patients from Beta‐AARC cohort were invited via email to FLAME remote and unsupervised assessment. 249 participants completed FLAME tasks, that include working memory (Self Ordered Search Score, Paired Associate Learning Score, Digit Span Score), episodic memory (Picture Recognition Accuracy), attention (Digit Vigilance Accuracy, Digit Vigilance False Alarms, Digit Vigilance Reaction Time Mean, Choice Reaction Time Accuracy) and executive function (Verbal Reasoning Accuracy). Analysis of covariance (ANCOVA) with post‐hoc (Tukey) were used to examine differences by clinical and amyloid status. Logistic regression models were employed to evaluate if the digital tasks predicted MCI. All analyses were adjusted for age, sex, and education.
Result
MCI group showed reduced performance in paired associate learning score, attention variables, picture recognition accuracy and verbal reasoning compared to CN and SCD participants. Digit vigilance false alarms, picture recognition accuracy and verbal reasoning accuracy were able to significantly distinguish between CN and SCD groups (Figure 1).
Several cognitive variables significantly predicted MCI, including paired associate learning score (OR=1.93,95%CI[1.09‐3.51],p=0.02), digit vigilance accuracy (OR=1.17,95%CI[1.02‐1.35],p=0.02) and false alarms (OR=1.4,95%CI[1.13‐1.76],p=0.002), and accuracy from choice reaction time task (OR=1.23,95%CI[1.03‐1.47],p=0.01), picture recognition (OR=1.39,95%CI[1.17‐1.72],p<0.001), and verbal reasoning (OR=1.05,95%CI [1.01‐1.11],p=0.03).
Additionally, self ordered search score and picture recognition accuracy were significantly lower in amyloid‐positive individuals (Figure 2).
Conclusion
A remote unsupervised assessment reliably differentiates diagnostic and AD biomarker‐defined groups and predicts MCI, underscoring its promise value for research and clinical contexts.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
2 Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, Hospital del Mar Research Institute (IMIM), Barcelona, Spain
3 College of Medicine and Health, University of Exeter, Exeter, UK
4 Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, Hospital del Mar Research Institute (IMIM), Barcelona, Spain, Servei de Neurologia, Hospital del Mar, Barcelona, Spain, Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain
5 Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, AstraZeneca, Barcelona, Spain
6 Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, Hospital del Mar Research Institute (IMIM), Barcelona, Spain, Department of Clinical Sciences, Clinical Memory Research Unit, Lund University, Lund, Spain
7 Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, Hospital del Mar Research Institute (IMIM), Barcelona, Spain, Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain





